Small molecule · Inhibitor of Heat shock factor 1 (HSF1) · developed by Nuvectis Pharma
NXP800 is an orally bioavailable small molecule that inhibits the HSF1 pathway, preventing HSF1-mediated transcription of genes that support tumor proliferation, migration, survival and metastasis. It is being studied in advanced solid tumors and ovarian cancers, including ARID1A-mutated disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05226507 | Phase 1 | Advanced Solid Tumor | Terminated | NVCT |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorARID1A Gene MutationOvarian CancerOvarian Clear Cell AdenocarcinomaOvarian Clear Cell CarcinomaOvarian Clear Cell TumorOvarian Endometrioid AdenocarcinomaOvarian Endometrioid Tumor
Updated Oct 25, 2026. Something wrong or missing? Report it on the NVCT page.
See NVCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVCT catalysts and pipeline →